Content |
Main article: Healthcare in Belarus
2024
Growth in the volume of drug production in Belarus to ₽68 billion
The volume of pharmaceutical production in Belarus in 2024 amounted to Br2,5 billion (about ₽68 billion). This was announced by the Deputy Minister of Health of Belarus Alexander Starovoitov on October 14, 2025.
According to BelTA, the country's authorities are planning to increase the volume of manufactured drugs. In 2026, it is planned to exceed the threshold of Br3 billion (about ₽81 billion). Deputy Minister of Health Alexander Starovoitov explained the strategic goals of the development of the industry.
Over the past five years, more than 390 names of demanded drugs have been developed and mastered in Belarus. Among them is the first domestic drug in the form of a solution for inhalation, which is used for the therapy of chronic lung diseases. The production of drugs for the treatment of diabetes mellitus, heart disease and acne has been mastered.
The pharmaceutical industry of Belarus is represented by 40 enterprises. Organizations of both state and private ownership operate in the industry. Production facilities provide a wide range of medicines for the domestic market and export.
Alexander Starovoitov noted that Belarus has become the only country in the post-Soviet space that has not abandoned its own pharmaceutical production at the state level. The head of state supported this decision. There are eight state-owned pharmaceutical industry enterprises in the Republic of Belarus. They produce a significant part of the drugs that are used by the population of the country.
All production sites are certified for compliance with the national requirements of Good Pharmacy Practice. Belarusian enterprises received 50 GMP certificates of the Republic of Belarus. 48 certificates of compliance with GMP rules of the Eurasian Economic Union were also issued. The certification system confirms the compliance of the production with international quality standards.[1]
Market Structure and Dynamics
The Belarusian pharmaceutical market is showing steady growth both in rubles and in packages. The dietary supplements segment is developing especially quickly - vitamins, mineral additives and lipid-lowering agents are among the most popular. Pricing is sensitive to currency fluctuations and logistics costs, but the share of drugs in the consumer basket of the population remains stable - about 4%. Such information is given in the analytical review of the pharmaceutical market in Belarus, published by the digital hub Wunder Digital on August 6, 2025.
According to analysts, the sphere remains low-elastic: the demand for medicines is weakly dependent on the price or income of the population. This changes the structure of consumption:
- prescription preparations remain stable;
- the share of conditionally over-the-counter drugs (especially cardiological) is growing;
- reduced proportion of completely over-the-counter drugs.
The total assortment on the market exceeds 5,000 items. Rotations occur annually: approximately 450 drugs go away and the same number come. Generics account for 72% of the market.
In terms of regional sales structure, the Minsk region is in the lead - this is explained by the high population size and its purchasing power. Among the key players in the market are: Lekpharm, Borisov ZMP, Belmedpreparaty, KRKA, GmbH Sandoz.
In the niche of dietary supplements, the greatest demand is observed for vitamins, mineral complexes and lipid-lowering agents.
In the category of oral health care products, the brands COREGA, LACALUT, ROKS are leading - together they occupy 63% of the market.
In the segment of pharmacy cosmetics, the main share is formed by DERMEDIC, LA ROCHE-POSAY and AVENE - a total of 22% of sales.
The leading positions are occupied by private chains: Pharmacy-Group, Interfarmax, Brititrade. In total, 35 pharmaceutical enterprises operate in the country, while 8 of the top 10 in terms of sales are Belarusian. Leaders: Iskamed, Belpharm, Lecpharm, Borymede, Farmland.
As noted in Wunder Digital, over the past years, the share of domestic drugs in the domestic market of Belarus has been maintained at at least 50%. Of these, half are produced by state-owned enterprises.
About 50% of the nomenclature produced by Belarusian pharmaceutical enterprises falls on drugs worth up to $2, and 26% - up to $1. These figures highlight the pronounced social focus of the pharmaceutical industry and its focus on the availability of treatment.
Over the past five years, 429 new drugs have been mastered and put on the market in the country. In total, as of the beginning of August 2025, about 4,200 names of drugs were registered in Belarus, of which approximately 1,750 are produced by local manufacturers.
As part of the pharmaceutical industry development program until 2030, 22 investment projects are being implemented in Belarus for a total amount of more than 900 million Belarusian rubles. Of these:
- 18 projects are aimed at expanding and modernizing production facilities;
- 3 projects for construction and renovation of warehouse infrastructure;
- 1 project to create a new research laboratory.
Against the background sanctions , the government stepped up diversification of supplies. Drugs are being localized, cooperation with, is expanding, and - China Russia Iran Cuba all for the sake of ensuring internal stability.
The government is consistently implementing a course on import substitution. Pharmacy chains are increasingly offering Belarusian drugs as an alternative to foreign ones, and also receive appropriate recommendations for their promotion. The authorities are considering a return to the reference pricing mechanism: setting prices for imported drugs based on comparative analysis with prices in other countries.
Since 2025, important changes in the regulation of distance trading have come into force:
- lifted the ban on the online sale of dietary supplements of all types, over-the-counter and veterinary drugs;
- an increase in the number of online pharmacies, booking services and online ordering is expected;
- in the future, the legalization of online trading in prescription drugs is allowed.
This opens up new opportunities for business, but is accompanied by increased regulatory control: over the activities of bloggers in medical topics; prices for medicines, medical services and products; compliance with the legislation on personal data.
Since 2024, foreign advertisers can only post advertizing in Belarus through local advertising agencies. Direct contracts with advertisers are now prohibited, and everyone who provides services for the placement of Internet advertising is required to be included in a special register. Violations entail significant fines - up to 500 basic values with confiscation of income.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |